Plain-English translation of NCT06444880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , either by itself or combined with another immunotherapy drug called , to treat certain rare cancers (renal medullary carcinoma and epithelioid sarcoma) that have specific genetic changes. These are aggressive cancers that have progressed despite previous treatment. The study will measure how well the medication works and how safe it is for patients.
These rare cancers are very difficult to treat and patients often run out of effective options after their first treatments fail. This trial exists because researchers believe that targeting a specific protein (called MUC16) on cancer cells using this medication might help patients whose tumors have these genetic changes.
You would start by receiving the first medication alone by IV infusion once per week for 4 weeks, then every 3 weeks afterward. If your cancer worsens after 6 weeks, you would move to the second phase and receive both medications together. Infusions start at about 4 hours but may become shorter as treatment continues. The study involves regular visits for blood work, imaging scans to check your cancer, and monitoring for side effects. The trial is currently closed to new enrollment, so participation would only be possible if it reopens.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Regeneron Pharmaceuticals
Enrollment target
~15 participants
Started
October 2024
Primary completion
July 2027
Age range
12 Years and older
Last updated on clinicaltrials.gov in August 2026.